Albuterol is a 50:50 mixture of R-albuterol, the active enantiomer, and S-a
lbuterol, which appears to be inactive in humans. The Food and Drug Adminis
tration recently approved levalbuterol, the pure K-isomer, as a preservativ
e-free nebulizer solution. Published studies indicate that it is neither sa
fer nor more effective than an equimolar dose of racemic albuterol (levalbu
terol 1.25 mg = albuterol 2.5 mg). However, these studies were conducted in
patients with stable asthma (at the top of the dose-response curve), where
as a nebulized bronchodilator most likely would be used by patients with an
acute exacerbation. Because such patients, in the hospital setting, often
require higher doses of albuterol, the manufacturer's recommended dose of l
evalbuterol is likely to be too low for rescue therapy. Levalbuterol may co
st as much as 5 times more than racemic albuterol, depending on purchase me
thod. We conclude that levalbuterol offers no advantage over albuterol but
is likely to be more costly.